The Use of Genetic Information to Define Idiopathic Pulmonary Fibrosis in UK Biobank.

"Financial/Nonfinancial Disclosures The authors have reported to CHEST the following: L. V. W. reports current and recent research funding from GSK, Genentech, and Orion Pharma and consultancy for Galapagos. R. G. J. is a trustee of Action for Pulmonary Fibrosis and reports personal fees from Astra Zeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Chiesi, Daewoong, Galapagos, Galecto, GlaxoSmithKline, Heptares, NuMedii, PatientMPower, Pliant, Promedior, Redx, Resolution Therapeutics, Roche, Veracyte, and Vicore. J. K. Q. has received grants from The Health Foundation, MRC, GSK, Bayer, BI, AUK-BLF, HDR UK, Chiesi. and AZ and personal fees for advisory board participation or speaking fees from GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Chiesi, Insmed and Bayer. None declared (O. C. L., R. J. A., L. M. K, A. D. M., M. D. T.)."

"Funding/Support L. V. W. holds a GSK/Asthma+Lung UK Chair in Respiratory Research (C17-1). L. V. W. and R. G. J. are supported by MRC Programme grant MR/V00235X/1. R. J. A. is an Action for Pulmonary Fibrosis Research Fellow. R. G. J. is supported by a National Institute for Health Research (NIHR) Research Professorship (NIHR reference RP-2017-08-ST2-014). L. M. K. was funded by a Medical Research Council (MRC) PhD studentship (MR/N013913/1). M. D. T. is supported by a Wellcome Trust Investigator Award (WT202849/Z/16/Z). A CC BY or equivalent license is applied to the Author Accepted Manuscript arising from this submission, in accordance with the grant’s open access conditions. The research was partially supported by the NIHR Leicester Biomedical Research Centre; This research has been conducted using the UK Biobank Resource under application 77050. This research used the SPECTRE High Performance Computing Facility at the University of Leicester."